SPRC
SciSparc
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 2
Price Hits New Low
Price Hits 52-week low
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About SPRC
Scisparc Ltd.
A company that develops Cannabinoid technologies in treatment of central nervous system disorders
20 Raul Wallenberg St., Tower A, 2nd Floor, Tel Aviv 6971916, Israel
--
SciSparc Ltd., a pharmaceutical company, was incorporated and started operations in Israel on August 23, 2004. The company is a clinical professional pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. Based on this, the company is currently working on the following development projects based on Δ 9-tetrahydrocannabinol (THC) and non-psychoactive cannabinol (CBD): THX-110 for the treatment of Tourette's syndrome (TS) and obstructive sleep apnea; THX-160 for the treatment of chronic and acute pain; and THX-210 for the treatment of chronic and acute pain, autism spectrum disorder and epilepsy.
Company Financials
EPS
SPRC has released its 2016 Q4 earnings. EPS was reported at -0.80, versus the expected 0.00, missing expectations. The chart below visualizes how SPRC has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
